对患心力衰竭风险增加的老年和肥胖患者使用恩帕格利弗洛辛:帝国预防试验计划的研究协议
Camilla Fuchs Andersen1, Julie Hempel Larsen2, Jesper Jensen1
1Department of Cardiology, Herlev-Gentofte University Hospital, Denmark; Faculty of Health and Medical Sciences, Copenhagen University, Denmark.
American heart journal
|February 16, 2024
概括
这项研究调查了empagliflozin用于预防心力衰竭在没有糖尿病的高风险患者. 它探讨了心脏和代谢的影响,旨在提供有关SGLT2抑制剂益处的早期见解.
科学领域:
- 心脏病学 心脏病学
- 代谢障碍 代谢障碍 代谢障碍
- 药理学 药理学是指药理学的学科.
背景情况:
- -葡萄糖共运输体2 (SGLT2) 抑制剂在2型糖尿病患者中表现出心脏保护作用.
- 这表明它在预防心力衰竭 (HF) 中可能发挥作用.
研究的目的:
- 评估Empagliflozin对心脏,新陈代谢和脏的影响,以预防HF.
- 评估empagliflozin在没有糖尿病或已确定的HF的高风险患者中的潜力.
- 为SGLT2抑制的益处提供机理性见解.
主要方法:
- 研究人员发起的,双盲的,随机的临床试验计划 (帝国预防).
- 包括老年人,肥胖患者 (60-84岁,BMI>28公斤/米2).
- 患者有高血压,心血管或慢性病,但没有糖尿病或HF.
- 随机 1:1 分给每天10毫克的empagliflozin或安慰剂180天.
- 主要终点包括身体能力,心脏结构变化,心上脂肪组织和细胞外体积.
主要成果:
- 目前,在204名患者中,有138名患者被随机分类.
- 在基线和随访时进行了全面的检查.
- 无论结果如何,数据都将被传播.
结论:
- 这项试验是评估SGLT2抑制在非糖尿病,高风险门诊环境中预防HF的第一步.
- 它将通过提供对SGLT2抑制剂的机制理解来补充更大的试验.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
201
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
201
01:22Heart Failure Drugs: Diuretics
381
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
381
01:22Heart Failure Drugs: β-Blockers
340
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
340
01:23Dipeptidyl Peptidase 4 Inhibitors
187
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
187
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K